Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222887 | 0.89 | L3MBTL1 (0.45) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL2112349 | 0.85 | PIM1 (0.40) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL31330259 | 0.85 | PIM1 (0.40) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL3755156 | 0.85 | PIM1 (0.40) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL31407790 | 0.85 | PIM1 (0.40) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL661642 | 0.84 | L3MBTL1 (0.41) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL29951804 | 0.84 | L3MBTL1 (0.41) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL30940053 | 0.83 | MEN1 (0.41) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL13079977 | 0.83 | MEN1 (0.41) | L3MBTL1ELANEPIM1MARK3MAP4K2 | |
| SCHEMBL13079979 | 0.83 | L3MBTL1 (0.51) | L3MBTL1ELANEPIM1MARK3MAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20080146814-A1 | Process for producing N-protected boryl compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146814-A1 | Process for producing N-protected boryl compounds | PBK, NME2, ZC3HAV1 | L3MBTL1 1115/4885ELANE 2397/4885PIM1 1231/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | L3MBTL1 1271/4885ELANE 2842/4885PIM1 2034/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | L3MBTL1 3418/4885ELANE 2436/4885PIM1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.